leisure time -WSS

leisure time

author：hotspot 2025-08-03 10:45:04 - browse：8271

Illustration of a red heart. -- health coverage from STAT — Adobe

Novo Nordisk’s obesity drug Wegovy cut the risk of major heart complications by 20% in a closely watched trial, results that could streamline insurance coverage and spur even greater demand for the highly popular therapy.

The milestone Select trial of about 17,500 patients is the first to show that an obesity medication leads to long-term cardiovascular benefits. The company reported only the topline figure in a press release Tuesday, and did not break out the reductions it said were seen in heart attacks, strokes, and cardiovascular deaths — the combined components of the study’s primary outcome. It said all three contributed to the decrease in cardiovascular events in the group that received Wegovy compared with participants given a placebo.

The 20% reduction was greater than many observers were expecting. In a research note Tuesday, Jefferies analysts called the results a “best case” outcome. “If they play baseball in Denmark,” Barclays analyst Emily Field wrote in a note, “Wegovy just hit a home run.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Pregnant women don't need prenatal multivitamins, study concludes

focus

WSS

Change Healthcare: What is it, why does its cyberattack matter?

Medicare drug price negotiation hearing pits pharma v Biden admin

Has Bernie Sanders reached the limit of his pharma bullying effort?

Why Talkspace is targeting Medicare, a tricky market

Most antidepressants don't work on kids, teens, study finds

Empower primary care with adequate payments and technology

hotspot

leisure time

entertainment

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

HHS's proposed rule does nothing to address the climate crisis

BioMarin wins approval for gene therapy to treat hemophilia A

HHS's proposed rule does nothing to address the climate crisis

Affirmative action in medical school literally saved lives

Ancient Greek ideas underpin modern concepts of pregnancy

Alkermes shareholders re

Lawmakers grill UnitedHealth CEO on Change cyberattack

How to save PrEP access — and even expand it

Welsh Carson private equity firm escapes from FTC antitrust case

focus

HHS's proposed rule does nothing to address the climate crisis

Novel spinal cord stimulator treats paralysis without surgery

Primary care doctor shortage won't be solved by free med school tuition

The effects of a landmark ruling on DNA ownership are becoming clearer

Harvard's David Sinclair gets blowback over aging

The public health thinking behind the CDC’s new Covid guidance

explore

focus

explore

knowledge